From Wikipedia, the free encyclopedia
|(what is this?)|
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.
Adverse drug effects
|This section is empty. You can help by adding to it. (October 2014)|
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|